Article Type

Original Study


Background: Because the aetiolo­gy of inflammatory bowel disease (IBD) is unclear, no causative therapy is available. However, pathophysiolo-gy of the disease offers a lot of possi­bilities to disrupt the inflammatory cascade that maintains the inflamma­tory process. Hyperleptinemia has been reported in acute inflammation especially during the early stage of in­testinal inflammation. This study was done to investigate the potential ther­apeutic effect of B3 adrenoreceptor agonist BRI 37344 (BRI) and com­pare it with the traditional used pred-nisolone in an experimental model of inflammatory bowel disease. Methods : The present study was done on 40 rats. They were divided into 2 main groups: Group I: 10 rats, as control group, received distilled water. Group II: 30 rats, subdivided into 3 equal subgroups as follow: Subgroup lla: indomethacin only treated group, received 7.5mg/kg in­domethacin for 2 doses separated by 24 hours, subcutaneously. Subgroup lib: indomethacin treated rats, re­ceived 0.5 mg/kg p red n is o I one intra-gastrically, with the 1st dose of indo­methacin and for 4 consecutive days. Subgroup lie: indomethacin treated rats, received 1 mg/kg BRI intragastri-cally at the same time with the 1st dose of indomethacin

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.